Terms: = Colorectal cancer AND CDKN1B, CDKN4, 1027, ENSG00000111276, MEN4, P27KIP1, P46527, MEN1B, KIP1 AND Treatment
108 results:
1. Selective but not pan-CDK inhibition abrogates 5-FU-driven tissue factor upregulation in colon cancer.
Kayser A; Wolff A; Berlin P; Duehring L; Henze L; Mundkowski R; Bergmann W; Müller-Hilke B; Wagner C; Huehns M; Oehmcke-Hecht S; Maletzki C
Sci Rep; 2024 May; 14(1):10582. PubMed ID: 38719932
[TBL] [Abstract] [Full Text] [Related]
2. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
Tassone P; Di Martino MT; Arbitrio M; Fiorillo L; Staropoli N; Ciliberto D; Cordua A; Scionti F; Bertucci B; Salvino A; Lopreiato M; Thunarf F; Cuomo O; Zito MC; De Fina MR; Brescia A; Gualtieri S; Riillo C; Manti F; Caracciolo D; Barbieri V; Di Paola ED; Di Francesco AE; Tagliaferri P
J Hematol Oncol; 2023 Jun; 16(1):68. PubMed ID: 37365583
[TBL] [Abstract] [Full Text] [Related]
3. Molecular profiling of colorectal cancer in a genetically admixed Hispanic population.
Montes-Rodríguez IM; Centeno-Girona H; Rivera-Lynch C; Rivera N; Cruz-Correa M
Cancer Med; 2023 May; 12(10):11686-11702. PubMed ID: 37039257
[TBL] [Abstract] [Full Text] [Related]
4. Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study.
Maleux G; Albrecht T; Arnold D; Bargellini I; Cianni R; Helmberger T; Kolligs F; Munneke G; Peynircioglu B; Sangro B; Schaefer N; Pereira H; Zeka B; de Jong N; Bilbao JI;
Cardiovasc Intervent Radiol; 2023 Jul; 46(7):852-867. PubMed ID: 36914788
[TBL] [Abstract] [Full Text] [Related]
5. Examination of colorectal cancer cases with metal allergy.
Mizukoshi K; Okazawa Y; Amemiya K; Tsuchiya Y; Motegi S; Tsukamoto R; Honjo K; Takahashi R; Yoshihara N; Kawano S; Kawai M; Munakata S; Ishiyama S; Sugimoto K; Takahashi M; Kojima Y; Ikeda S; Sakamoto K
Surg Today; 2023 Jul; 53(7):753-761. PubMed ID: 36757618
[TBL] [Abstract] [Full Text] [Related]
6. EMERGENCY SURGERY FOR OBSTRUCTING COLON cancer: MORBIDITY AND RISK FACTORS OF EARLY POSTOPERATIVE MORTALITY - A COHORT STUDY OF 118 CASES.
Zaafouri H; Cherif M; Khedhiri N; Mesbahi M; Zebda H; Jouini R; Bellali H; Ben Maamer A
Arq Bras Cir Dig; 2023; 35():e1706. PubMed ID: 36629687
[TBL] [Abstract] [Full Text] [Related]
7. AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy.
de Almeida LC; Carlos JAEG; Rezende-Teixeira P; Machado-Neto JA; Costa-Lotufo LV
Life Sci; 2022 Nov; 308():120911. PubMed ID: 36030982
[TBL] [Abstract] [Full Text] [Related]
8. Functional assessment of miR‑1291 in colon cancer cells.
Wang J; Yokoyama Y; Hirose H; Shimomura Y; Bonkobara S; Itakura H; Kouda S; Morimoto Y; Minami K; Takahashi H; Shibata S; Kobayashi S; Uemura M; Tanaka S; Wu X; Tanaka S; Mori M; Yamamoto H
Int J Oncol; 2022 Feb; 60(2):. PubMed ID: 34981812
[TBL] [Abstract] [Full Text] [Related]
9. RAS specific protease induces irreversible growth arrest via p27 in several KRAS mutant colorectal cancer cell lines.
Stubbs CK; Biancucci M; Vidimar V; Satchell KJF
Sci Rep; 2021 Sep; 11(1):17925. PubMed ID: 34504197
[TBL] [Abstract] [Full Text] [Related]
10. Achalasia and acromegaly: Co-incidence of these diseases or a new syndrome?
Dolina J; Kunovsky L; Kroupa R; Stary K; Jabandziev P; Nesporova T; Maca K; Andrasina T; Marek F; Kala Z; Vaculova J; Said D; Zapletalova M; Lochman J; Palova Noskova H; Slaby O; Izakovicova Holla L; Borilova Linhartova P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 May; 166(2):228-235. PubMed ID: 34282806
[TBL] [Abstract] [Full Text] [Related]
11. State-of-the-art colorectal disease: postoperative ileus.
Sommer NP; Schneider R; Wehner S; Kalff JC; Vilz TO
Int J Colorectal Dis; 2021 Sep; 36(9):2017-2025. PubMed ID: 33977334
[TBL] [Abstract] [Full Text] [Related]
12. A New CYP2E1 Inhibitor, 12-Imidazolyl-1-dodecanol, Represents a Potential treatment for Hepatocellular Carcinoma.
Diesinger T; Lautwein A; Bergler S; Buckert D; Renz C; Dvorsky R; Buko V; Kirko S; Schneider E; Kuchenbauer F; Kumar M; Günes C; Genze F; Büchele B; Simmet T; Haslbeck M; Masur K; Barth T; Müller-Enoch D; Wirth T; Haehner T
Can J Gastroenterol Hepatol; 2021; 2021():8854432. PubMed ID: 33604316
[TBL] [Abstract] [Full Text] [Related]
13. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ;
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085
[TBL] [Abstract] [Full Text] [Related]
14. Intestinal PPARα Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6.
Luo Y; Xie C; Brocker CN; Fan J; Wu X; Feng L; Wang Q; Zhao J; Lu D; Tandon M; Cam M; Krausz KW; Liu W; Gonzalez FJ
Gastroenterology; 2019 Sep; 157(3):744-759.e4. PubMed ID: 31154022
[TBL] [Abstract] [Full Text] [Related]
15. ZNF692 promotes colon adenocarcinoma cell growth and metastasis by activating the PI3K/AKT pathway.
Xing Y; Ren S; Ai L; Sun W; Zhao Z; Jiang F; Zhu Y; Piao D
Int J Oncol; 2019 May; 54(5):1691-1703. PubMed ID: 30816443
[TBL] [Abstract] [Full Text] [Related]
16. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.
Schally AV; Wang H; He J; Cai R; Sha W; Popovics P; Perez R; Vidaurre I; Zhang X
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12028-12033. PubMed ID: 30373845
[TBL] [Abstract] [Full Text] [Related]
17. Alternative NF-κB signaling promotes colorectal tumorigenesis through transcriptionally upregulating Bcl-3.
Tao Y; Liu Z; Hou Y; Wang S; Liu S; Jiang Y; Tan D; Ge Q; Li C; Hu Y; Liu Z; Chen X; Wang Q; Wang M; Zhang X
Oncogene; 2018 Nov; 37(44):5887-5900. PubMed ID: 29973688
[TBL] [Abstract] [Full Text] [Related]
18. Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells.
Jiang D; Li J; Li J; Wang M; Han C; Wang X; Zhao C; Ye Y
Int J Oncol; 2017 Nov; 51(5):1611-1620. PubMed ID: 29048661
[TBL] [Abstract] [Full Text] [Related]
19. Induction of p53-Independent Apoptosis and G1 Cell Cycle Arrest by Fucoidan in HCT116 Human colorectal Carcinoma Cells.
Park HY; Park SH; Jeong JW; Yoon D; Han MH; Lee DS; Choi G; Yim MJ; Lee JM; Kim DH; Kim GY; Choi IW; Kim S; Kim HS; Cha HJ; Choi YH
Mar Drugs; 2017 May; 15(6):. PubMed ID: 28555064
[TBL] [Abstract] [Full Text] [Related]
20. Analysis of expression of cyclin E, p27kip1 and Ki67 protein in colorectal cancer tissues and its value for diagnosis, treatment and prognosis of disease.
Li W; Zhang G; Wang HL; Wang L
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(23):4874-4879. PubMed ID: 27981549
[TBL] [Abstract] [Full Text] [Related]
[Next]
